FKC288 for Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis

Summary

This study is a single-center exploratory clinical trial. It is estimated that 6-12 subjects will be enrolled. The "BOIN" dose escalation design is adopted. The main purpose is to evaluate the safety of FKC288 in the treatment of subjects with relapsed or refractory AL amyloidosis and explore the recommended phase II dose of FKC288 in the treatment of patients with relapsed/refractory systemic Light Chain (AL) amyloidosis.

Timeline

Start

2023-08-29

Primary completion

2025-06

Completion

2026-06

Publications

• Huang X, Wu X, Chen W, Wang W, Xu W, Guo J, Zhao J, Xu X, Wang C, Shan A, Xu J, Liu Z. B -Cell Maturation Antigen-CD19 Dual-Targeted Chimeric Antigen Receptor- T -Cell Therapy for Relapsed or Refractory AL Amyloidosis. J Am Soc Nephrol. 2026 Apr 1. doi: 10.1681/ASN.0000001096. Online ahead of print.

Drugs

Indications